Health Advances

FEBRUARY 22, 2023

Pricing biosimilars with PBMs in mind will likely generate attractive returns on investment for early-to-market biosimilars but may only result in limited cost-savings for patients or the healthcare system at large. from 2021 to 2025 [2], with nearly two-thirds of savings resulting from downward price pressure on the reference molecule.

Pharmaceuticals 52

Pharmaceuticals Medicare Medicaid Healthcare 52

NASHP

JULY 22, 2022

Expanded Federal Investment in Home and Community-Based Services: State Approaches to Serve Children and Youth July 22, 2022 / by Zack Gould and Kate Honsberger. In addition to improving quality of life for those who receive them, HCBS have also been shown to provide significant cost savings to states when compared with residential care.[4]

Medicaid 106

Medicaid Rehabilitation Nursing Medicare 106

Vie Healthcare

FEBRUARY 22, 2023

it kind of reflects probably what my true passion really is and it’s teaching, it’s coaching, it’s advising, it’s helping others, all high performing professionals, but especially nurses, nurse practitioners, to really find their true profession and their true passion and where they want to go in their profession.

Healthcare 52

Healthcare Nursing Doctors Performance improvement 52